Meta AnalysisID 6322
芪苈强心胶囊联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭：一项系统评价与Meta分析
CRD42022306897
To systematically assess the safety and effectiveness of Qili Qiangxin Capsule combined with sacubitril/valsartan in the treatment of HFrEF
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6322
- Evidence Id
- 14880
- Core Evidence Id
- 14880
- Source Meta Analysis Id
- 6307
- Herb2 Meta Analysis Id
- HBMA006307
- Crd Id
- CRD42022306897
- Title
- Qili Qiangxin Capsule combined with sacubitril/valsartan for HFrEF: a systematic review and meta-analysis
- Review Question
- To systematically assess the safety and effectiveness of Qili Qiangxin Capsule combined with sacubitril/valsartan in the treatment of HFrEF
- Study Type Included
- Randomized clinical trials will be included irrespective of blinding, publication status or language.
- Condition Being Studied
- Heart failure (HF) is the symptoms and/or signs of heart failure caused by abnormal heart structure and/or function, usually accompanied by elevated natriuretic peptide levels and/or objective evidence of cardiogenic pulmonary circulation or systemic congestion. And the objective evidences including imaging clinical syndromes such as physical examination, resting or load hemodynamic monitoring, etc. European Society of Cardiology (ESC) divided HF into 3 types namely HF with preserves ejection fraction (HFpEF, LVEF > 50%), HF with midrange ejection fraction (HFmrEF, LVEF 40–49%) and HF with reduced ejection fraction (HFrEF, LVEF < 40%) in 2016 . A report based on the global burden of disease showed that the number of patients with HF has increased from 33.5 million in 1990 to 64.3 million in 2017 , the increase almost doubled, and continues to grow rapidly due to the aging of the population. According to “China Cardiovascular Disease Report 2018”, there are about 5 million heart failure patients in China, and the 5-year average survival rate is about 50%, 10-year average survival rate is only 10%.Therefore, this study intend to systematically evaluate the efficacy and safety of Qili Qiangxin Capsule combined with sacubitril/valsartan for HFrEF, so as to provide reference for clinical practice.
- Participant
- Adults with HFrEF (as diagnosed by a clinician, or using any recognized diagnostic criteria) will be included.
- Animal
- Human Disease Modelled
- Intervention
- The intervention should be QQC combined with sacubitril/valsartan, whether it combined with other western medicine treatments or not.
- Comparator Control
- The control group should be sacubitril/valsartan, whether it combined with other western medicine treatments or not.
- Main Outcome
- Primary outcome measures including the left ventricular ejection fractions(LVEF), left ventricular end-diastolic dimension (LVEDD), left ventricular end-Systolic diameter (LVESD), N-terminal pro-B-type natriuretic peptide level(NT-proBNP), brain natriuretic peptide level(BNP), 6 minute walking distance (6-MWD), stroke volume (SV). Measures of effect Mean difference (MD) was used to represent continuous variable data; Odds Ratio (OR) was used to represent binary variable data. 95% confidence interval (CI) was used to evaluate each effect index. When the 95% CI of MD does not include 0 or the 95% CI of or does not include 1, the difference between the two intervention methods was statistically significant (P<0.05)
- Outcome Measure
- Additional Outcome
- Secondary outcome measure including aldosterone level(ALD), angiotensin II level (Ang-Ⅱ), and the adverse events. Measures of effect Mean difference (MD) was used to represent continuous variable data; Odds Ratio (OR) was used to represent binary variable data. 95% confidence interval (CI) was used to evaluate each effect index. When the 95% CI of MD does not include 0 or the 95% CI of or does not include 1, the difference between the two intervention methods was statistically significant (P<0.05).
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Heart Failure; Humans; Stroke Volume; Valsartan; qiangxin; sacubitril
- Contact
- Xiaohu Chen [email protected]
- Organisational Affiliation
- Nanjing University of Traditional Chinese Medicine
- Funding Source
- This study was supported by the National Natural Science Foundation of China (81973824), the National Administration of Traditional Chinese Medicine: 2019 Project of building evidence based practice capacity for TCM (2019XZZXXXG004), the Jiangsu Province Traditional Chinese Medicine Leading Talent Project (SLJ0204), the Jiangsu Administration of Traditional Chinese Medicine (ZD201703), the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) and the fifth phase of “Project 333” scientific research project of Jiangsu Province.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Trad, English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-02-13
- Registration Date
- 2022-03-16
- Anticipated Start Date
- 2022-02-14
- Anticipated Completion Date
- 2022-04-01
- Title Cn
- 芪苈强心胶囊联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭：一项系统评价与Meta分析
- Title En
- Qili Qiangxin Capsule combined with sacubitril/valsartan for HFrEF: a systematic review and meta-analysis
- Bilingual Status
- complete